SCYNEXIS Secures $40M in Securities Purchase Agreement
- Financing Agreement Details: SCYNEXIS has entered into a securities purchase agreement with institutional investors, anticipating upfront gross proceeds of approximately $40M, with an additional $52.2M available if common warrants are fully exercised, indicating strong market confidence in its future.
- Share Issuance Plan: The company will issue 34.75M shares of common stock and 8.75M pre-funded warrants, along with common warrants for 43.5M shares, reflecting a proactive adjustment in its capital structure aimed at enhancing liquidity.
- Use of Proceeds: The net proceeds from this financing will be allocated for working capital and general corporate purposes, with estimates suggesting that these funds will support operations into mid-2029, ensuring ongoing investment in R&D and market expansion.
- Market Reaction: SCYNEXIS's stock rose 3.83% in pre-market trading to $0.82, reflecting positive investor sentiment towards the company's financing strategy and recognition of its growth potential.
Trade with 70% Backtested Accuracy
Analyst Views on SCYX
No data
About SCYX
About the author
Scynexis Acquires Kidney Disease Treatment, Shares Surge
- Stock Surge: Scynexis, Inc. (SCYX) shares rose approximately 10% in pre-market trading on Tuesday, primarily driven by the announcement of a deal to acquire a potential kidney disease treatment from Poxel S.A.
- Acquisition Details: Scynexis signed a definitive agreement to acquire PXL-770, now renamed SCY-770, a novel oral therapy aimed at treating Autosomal Dominant Polycystic Kidney Disease, a leading cause of kidney failure.
- Clinical Trial Progress: The drug has demonstrated a favorable safety profile across eight clinical trials, with plans to initiate a Phase 2 study in late 2026 and early results expected in the second half of 2027.
- Funding Strategy: Scynexis expects to raise about $40 million upfront from a private placement, with the potential for an additional $52.2 million if all warrants are exercised for cash, thereby strengthening its financial position to support ongoing research and development.
Poxel SA Sells Drug Candidate PXL770 to Scynexis for Up to $196 Million
- Significant Transaction Value: Poxel SA has agreed to sell its drug candidate PXL770 to Scynexis for up to $196 million, including an upfront payment of $8 million and additional payments tied to development and commercial milestones, indicating strong market recognition of the drug's potential.
- Clinical Trial Plans: A Phase 2 proof-of-concept study for autosomal dominant polycystic kidney disease is expected to begin in Q4 2026, with initial efficacy results anticipated in the second half of 2027, which will provide critical data for further drug development.
- Focus on Core Pipeline: Poxel SA plans to concentrate on its core pipeline, including TWYMEEG and PXL065, while pursuing new partnerships to create long-term value, demonstrating a strategic emphasis on the ongoing advancement of drug development.
- Positive Market Reaction: Poxel SA's stock rose 9.78% to €0.2525 on the Paris Stock Exchange, while Scynexis saw a 4.76% increase to $0.8273 in pre-market trading on Nasdaq, reflecting investor optimism regarding the transaction.
SCYNEXIS Reports 2025 Financial Highlights and Pipeline Progress
- Significant Revenue Growth: SCYNEXIS reported total revenue of $20.6 million for 2025, a substantial increase from $3.7 million in 2024, primarily driven by licensing agreement revenue from GSK, indicating strong performance in the antifungal market.
- Narrowed Net Loss: The company posted a net loss of $8.6 million in 2025, significantly down from $21.3 million in 2024, reflecting effective cost control and revenue growth, which enhances investor confidence.
- SCY-247 Clinical Progress: SCY-247, a second-generation antifungal drug, is currently in Phase 1 clinical trials, with early results demonstrating good tolerability and strong pharmacokinetics, with topline data for the IV formulation expected in the second half of 2026.
- BREXAFEMME Relaunch Plans: Despite the recall of BREXAFEMME in 2023 due to manufacturing issues, GSK is preparing for its relaunch, and SCYNEXIS stands to gain up to $145.5 million in annual net sales milestones and royalties, further strengthening its financial stability.
SCYNEXIS Secures FDA QIDP Designation for SCY-247, Ensuring 10 Years of Market Exclusivity
- FDA Designation: SCYNEXIS's SCY-247 has received QIDP and Fast Track designations from the FDA, ensuring at least 10 years of market exclusivity post-approval, thereby enhancing the company's competitive edge in the antifungal market.
- Clinical Trial Plans: The company expects to initiate a Phase 1 study of SCY-247 with the IV formulation and a Phase 2 study with the oral formulation in 2026, aiming to address the treatment needs for invasive candidiasis and further advance product development.
- Antifungal Activity: SCY-247 has demonstrated potent activity against various difficult-to-treat fungal pathogens, including multi-drug-resistant Candida auris, in multiple preclinical studies, indicating its potential to combat public health threats.
- Market Demand: As the threat of multi-drug resistant fungal infections escalates, the development of SCY-247 not only meets the urgent market need for novel antifungal agents but also holds the potential for significant economic returns for the company.
Scynexis Reveals Federal Support for Partnership Between Hackensack Meridian CDI and Johns Hopkins Researchers to Create Innovative Therapies, Including New Fungerps, for Resistant Fungal Infections
Federal Grant Announcement: SCYNEXIS, Inc. has received a five-year federal grant of $7 million annually to support the development of new antifungal therapeutics, particularly next-generation triterpenoid antifungals (fungerps), aimed at combating resistant fungal infections.
Research Collaboration: The grant will establish a Center of Excellence in Translational Research (CETR) in collaboration with Hackensack Meridian Center for Discovery and Innovation and Johns Hopkins Bloomberg School of Public Health, focusing on advancing fungerp candidates from preclinical stages to IND-ready status.
Fungal Infection Statistics: Approximately four million deaths annually are attributed to fungal infections globally, highlighting the urgent need for new therapeutics to address the growing threat of resistant fungal pathogens.
Triterpenoid Antifungals Overview: Triterpenoid antifungals represent a novel class of glucan synthase inhibitors, with the first compound, Ibrexafungerp, already approved for treating vulvovaginal candidiasis, while additional candidates are in various stages of development to tackle multidrug-resistant fungal infections.
SCYNEXIS Announces Financial Results for Q3 2025 and Shares Corporate Update
Financial Agreement with GSK: SCYNEXIS will receive $24.8 million from GSK as part of resolving a disagreement over the Phase 3 MARIO study, which SCYNEXIS has agreed to terminate. This payment will enhance the company's cash runway to over two years.
SCY-247 Development Progress: Following positive Phase 1 results for SCY-247, SCYNEXIS plans to initiate a Phase 1 study for its IV formulation and a Phase 2 study for invasive candidiasis, with proof of concept data expected in 2026.
Commitment to BREXAFEMME®: GSK is focused on relaunching BREXAFEMME®, with plans to transfer the NDA by year-end, potentially leading to SCYNEXIS receiving up to $146 million in annual sales milestones and royalties.
Q3 2025 Financial Results: SCYNEXIS reported a net loss of $8.6 million for Q3 2025, with total revenue primarily from license agreements. The company is managing its expenses effectively, resulting in a cash balance of $37.9 million as of September 30, 2025.
Scynexis Acquires Kidney Disease Treatment, Shares Surge
- Stock Surge: Scynexis, Inc. (SCYX) shares rose approximately 10% in pre-market trading on Tuesday, primarily driven by the announcement of a deal to acquire a potential kidney disease treatment from Poxel S.A.
- Acquisition Details: Scynexis signed a definitive agreement to acquire PXL-770, now renamed SCY-770, a novel oral therapy aimed at treating Autosomal Dominant Polycystic Kidney Disease, a leading cause of kidney failure.
- Clinical Trial Progress: The drug has demonstrated a favorable safety profile across eight clinical trials, with plans to initiate a Phase 2 study in late 2026 and early results expected in the second half of 2027.
- Funding Strategy: Scynexis expects to raise about $40 million upfront from a private placement, with the potential for an additional $52.2 million if all warrants are exercised for cash, thereby strengthening its financial position to support ongoing research and development.
Poxel SA Sells Drug Candidate PXL770 to Scynexis for Up to $196 Million
- Significant Transaction Value: Poxel SA has agreed to sell its drug candidate PXL770 to Scynexis for up to $196 million, including an upfront payment of $8 million and additional payments tied to development and commercial milestones, indicating strong market recognition of the drug's potential.
- Clinical Trial Plans: A Phase 2 proof-of-concept study for autosomal dominant polycystic kidney disease is expected to begin in Q4 2026, with initial efficacy results anticipated in the second half of 2027, which will provide critical data for further drug development.
- Focus on Core Pipeline: Poxel SA plans to concentrate on its core pipeline, including TWYMEEG and PXL065, while pursuing new partnerships to create long-term value, demonstrating a strategic emphasis on the ongoing advancement of drug development.
- Positive Market Reaction: Poxel SA's stock rose 9.78% to €0.2525 on the Paris Stock Exchange, while Scynexis saw a 4.76% increase to $0.8273 in pre-market trading on Nasdaq, reflecting investor optimism regarding the transaction.
SCYNEXIS Reports 2025 Financial Highlights and Pipeline Progress
- Significant Revenue Growth: SCYNEXIS reported total revenue of $20.6 million for 2025, a substantial increase from $3.7 million in 2024, primarily driven by licensing agreement revenue from GSK, indicating strong performance in the antifungal market.
- Narrowed Net Loss: The company posted a net loss of $8.6 million in 2025, significantly down from $21.3 million in 2024, reflecting effective cost control and revenue growth, which enhances investor confidence.
- SCY-247 Clinical Progress: SCY-247, a second-generation antifungal drug, is currently in Phase 1 clinical trials, with early results demonstrating good tolerability and strong pharmacokinetics, with topline data for the IV formulation expected in the second half of 2026.
- BREXAFEMME Relaunch Plans: Despite the recall of BREXAFEMME in 2023 due to manufacturing issues, GSK is preparing for its relaunch, and SCYNEXIS stands to gain up to $145.5 million in annual net sales milestones and royalties, further strengthening its financial stability.
SCYNEXIS Secures FDA QIDP Designation for SCY-247, Ensuring 10 Years of Market Exclusivity
- FDA Designation: SCYNEXIS's SCY-247 has received QIDP and Fast Track designations from the FDA, ensuring at least 10 years of market exclusivity post-approval, thereby enhancing the company's competitive edge in the antifungal market.
- Clinical Trial Plans: The company expects to initiate a Phase 1 study of SCY-247 with the IV formulation and a Phase 2 study with the oral formulation in 2026, aiming to address the treatment needs for invasive candidiasis and further advance product development.
- Antifungal Activity: SCY-247 has demonstrated potent activity against various difficult-to-treat fungal pathogens, including multi-drug-resistant Candida auris, in multiple preclinical studies, indicating its potential to combat public health threats.
- Market Demand: As the threat of multi-drug resistant fungal infections escalates, the development of SCY-247 not only meets the urgent market need for novel antifungal agents but also holds the potential for significant economic returns for the company.
Scynexis Reveals Federal Support for Partnership Between Hackensack Meridian CDI and Johns Hopkins Researchers to Create Innovative Therapies, Including New Fungerps, for Resistant Fungal Infections
Federal Grant Announcement: SCYNEXIS, Inc. has received a five-year federal grant of $7 million annually to support the development of new antifungal therapeutics, particularly next-generation triterpenoid antifungals (fungerps), aimed at combating resistant fungal infections.
Research Collaboration: The grant will establish a Center of Excellence in Translational Research (CETR) in collaboration with Hackensack Meridian Center for Discovery and Innovation and Johns Hopkins Bloomberg School of Public Health, focusing on advancing fungerp candidates from preclinical stages to IND-ready status.
Fungal Infection Statistics: Approximately four million deaths annually are attributed to fungal infections globally, highlighting the urgent need for new therapeutics to address the growing threat of resistant fungal pathogens.
Triterpenoid Antifungals Overview: Triterpenoid antifungals represent a novel class of glucan synthase inhibitors, with the first compound, Ibrexafungerp, already approved for treating vulvovaginal candidiasis, while additional candidates are in various stages of development to tackle multidrug-resistant fungal infections.
SCYNEXIS Announces Financial Results for Q3 2025 and Shares Corporate Update
Financial Agreement with GSK: SCYNEXIS will receive $24.8 million from GSK as part of resolving a disagreement over the Phase 3 MARIO study, which SCYNEXIS has agreed to terminate. This payment will enhance the company's cash runway to over two years.
SCY-247 Development Progress: Following positive Phase 1 results for SCY-247, SCYNEXIS plans to initiate a Phase 1 study for its IV formulation and a Phase 2 study for invasive candidiasis, with proof of concept data expected in 2026.
Commitment to BREXAFEMME®: GSK is focused on relaunching BREXAFEMME®, with plans to transfer the NDA by year-end, potentially leading to SCYNEXIS receiving up to $146 million in annual sales milestones and royalties.
Q3 2025 Financial Results: SCYNEXIS reported a net loss of $8.6 million for Q3 2025, with total revenue primarily from license agreements. The company is managing its expenses effectively, resulting in a cash balance of $37.9 million as of September 30, 2025.
